For the Inventor, By the Inventor

Enter assignee name

Nagasaki, Japan

Nagasaki University

Calculating rank

USPTO Granted Patents = 60

% Expired Patents = 55.0

EPO Patents = 16

Forward Citations = 61

Loading Chart...

Loading Chart...

145 inventors (with patents filed for the assignee):

Fujio Kurokawa (17 out of 19 patents)

Hiroshi Ueda (8 out of 9 patents)

Noboru Kitamura (4 out of 6 patents)

4. Keisuke Umakoshi (4 out of 4 patents)

5. Shoji Ishizaka (4 out of 4 patents)

6. Yoshimasa Tanaka (3 out of 7 patents)

7. Masayoshi Onishi (3 out of 3 patents)

8. Jiro Yasuda (2 out of 2 patents)

9. Hiroyuki Osuga (2 out of 12 patents)

10. Yuki Sakai (2 out of 2 patents)

11. Satoshi Mizuta (2 out of 2 patents)

12. Takashi Tanaka (2 out of 4 patents)

13. Susumu Eguchi (2 out of 2 patents)

14. Kouichi Morita (2 out of 3 patents)

15. Kazutoyo Kimura (2 out of 2 patents)

Core Competencies:

Dengue Virus Vaccine

Alzheimer's Disease

SARS-CoV-2 Detection

Liver Precursor Cells

Sarcopenia Treatment

Neurodegenerative Disease

Optically Active Compounds

Chronic Pain Treatment

Blood-Brain Barrier

Transgenic Models

Cytotoxicity Measurement

Antigen Delivery

60 patents: Sort by Forward Citations

1. 12478645 - Method for manufacturing cell population including liver precursor cells (2025-11-25),

2. 12317889 - Storage container (2025-06-03),

3. 12280099 - Dengue virus vaccine (2025-04-21),

4. 11559195 - Rigid endoscope cover and endoscope unit (2023-01-24),

5. 11345971 - Primer set for detecting SARS-CoV-2, method for testing SARS-CoV-2, and reagent and kit of testing SARS-CoV-2 (2022-05-31),

6. 11306317 - Method of producing isoprenoids and proteins, genes, and transformants for the same (2022-04-19),

7. 11286261 - Fourth-generation EGFR tyrosine kinase inhibitor (2022-03-29),

8. 10913949 - Therapeutic agent for sarcopenia and metabolic diseases (2021-02-09),

9. 10734726 - Wideband planar circularly polarized antenna and antenna device (2020-08-04),

10. 10563249 - Primer set for detection of Zaire ebola virus, assay kit, and amplification method (2020-02-18),

11. 10532065 - Bisphosphonic acid derivative and application for same (2020-01-14),

12. 10280188 - Fluorine-containing bisphosphonic acid derivative and use thereof (2019-05-07),

13. 10183007 - Method of producing proanthocyanidin oligomer (2019-01-22),

14. 10175229 - Rapid method for measuring cytotoxicity in non-RI system (2019-01-08),

15. 10130357 - Instrument for delivering a surgical thread (2018-11-20),

Company Overview

Nagasaki University, located in Nagasaki, Japan, is a prominent institution focused on biomedical innovations. The university is engaged in advanced research and development in various fields, including the creation of vaccines for diseases such as dengue and SARS-CoV-2, as well as therapies for neurodegenerative conditions like Alzheimer's disease. Additionally, it explores treatments for chronic pain and sarcopenia, and investigates liver precursor cells and optically active compounds, contributing significantly to global health advancements.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

60 Patents

#2 in Nagasaki

#1,534 in Japan

#12,098 in the World

Nagasaki, Japan

Nagasaki University

Forward Citations = 61

145 inventors:

Fujio Kurokawa (17 out of 19 patents)

Hiroshi Ueda (8 out of 9 patents)

Noboru Kitamura (4 out of 6 patents)

4. Keisuke Umakoshi (4 out of 4 patents)

5. Shoji Ishizaka (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nagasaki University. Retrieved from https://idiyas.com/company/nagasaki-university

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…